Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

BFBaijun FangPZPing ZhangJLJuan Li

Discussion

Loading...

Member takes

Overview

Clinical studies reveal aponermin and daratumumab improve outcomes in multiple myeloma, highlighting safety and efficacy.

Key Points

  • The research focuses on assessing the safety and efficacy of aponermin and daratumumab in treating multiple myeloma.
  • Retrospective analysis of clinical data from 14 multiple myeloma patients treated with aponermin and daratumumab-based regimens.
  • Evaluated overall response rate, duration of response, and adverse events.
  • Patients presented with varying stages of relapsed/refractory multiple myeloma and received different treatment combinations.
  • Overall response rate of 78.57%, with complete response in 14.29%, and very good partial response in 21.43%.
  • Median duration of response was 3.7 months with manageable adverse events reported.
  • Favorable safety profile, with minor hematologic toxicities but no hepatotoxicity observed.

Cite This Study

Fang et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e08dhttps://doi.org/10.1182/blood-2025-7580
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study2025
  2. 2Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma2025
  3. 3Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025
  4. 4Aponermin-based regimen as bridging therapy prior to CAR-T cell therapy for relapsed/refractory multiple myeloma2025
  5. 5Efficacy and Safety of Daratumumab‐Based Regimens in Multiple Myeloma: A Systematic Review and Meta‐Analysis of Phase III Randomized Controlled Trials2026